tiprankstipranks
Ayala Pharmaceuticals Inc (AYLA)
NASDAQ:AYLA
US Market
Holding AYLA?
Track your performance easily

Ayala Pharmaceuticals (AYLA) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

AYLA Analyst Ratings

Currently, no data available
Based on 0 analysts giving stock ratings to
Ayala
Pharmaceuticals
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

AYLA Stock 12 Month Forecast

There Are No Analyst Ratings for AYLA In The Last 3 Months.
Highest Price TargetAverage Price TargetLowest Price Target
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

AYLA Financial Forecast

No data currently available

AYLA Earnings Forecast

Currently, no earnings data available.
Currently, no earnings data available.
No data currently available

AYLA Sales Forecast

Currently, no sales data available.
Currently, no sales data available.

Detailed List of Analyst Forecasts​

Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Oppenheimer
Hold
Downgraded
10/31/22
Analysts' Opinions Are Mixed on These Healthcare Stocks: CSL (Other OTC: CMXHF) and Ayala Pharmaceuticals (NASDAQ: AYLA)
Ladenburg Thalmann & Co.
Hold
Downgraded
10/20/22
Ladenburg Thalmann downgrades Ayala Pharmaceuticals (AYLA) to NeutralLadenburg Thalmann analyst Ahu Demir downgraded Ayala Pharmaceuticals (NASDAQ: AYLA) from Buy to Neutral.
EF Hutton
$0.55
Sell
-1.79%
Downside
Downgraded
10/19/22
Ayala Pharmaceuticals (AYLA) downgraded to Sell from Buy at Roth Capital" Moreover, how the combined company is able to drive any clinical synergies has not been defined, he writes.
Noble Financial
Hold
Reiterated
10/07/22
Noble Financial Reaffirms Their Hold Rating on Ayala Pharmaceuticals (AYLA)
Raymond James
$6
Buy
971.43%
Upside
Reiterated
03/29/22
UPDATE: Ayala Pharmaceuticals (AYLA) PT Lowered to $6 at Raymond JamesRaymond James analyst Dane Leone lowered the price target on Ayala Pharmaceuticals (NASDAQ: AYLA) to $6.00 (from $24.00) while maintaining a Outperform rating.

AYLA Analyst Recommendation Trends

Currently, no data available
Please return soon. This page is being updated.
Each month's total comprises the sum of three months' worth of ratings.
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

AYLA Stock Forecast FAQ

What is AYLA’s average 12-month price target, according to analysts?
Currently, no data Available
What is AYLA’s upside potential, based on the analysts’ average price target?
Currently there's no upside potential for AYLA, based on the analysts’ average price target.
Can I see which stocks the top-ranking analysts are rating?
Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
    How can I follow the stock ratings of top Wall Street analysts?
    Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
      Is AYLA a Buy, Sell or Hold?
      Currently, no data Available
      What is Ayala Pharmaceuticals Inc’s price target?
      Currently, no data Available
      What do analysts say about Ayala Pharmaceuticals Inc?
      Not enough analysts have published a price target to provide an average price target.
      How can I buy shares of AYLA?
      Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.
        What am I Missing?
        Make informed decisions based on Top Analysts' activity
        Know what industry insiders are buying
        Get actionable alerts from top Wall Street Analysts
        Find out before anyone else which stock is going to shoot up
        Get powerful stock screeners & detailed portfolio analysis